Clinical Trials

Ongoing clinical trials in molecular imaging and radiotheranostics. Sorted by date of last update.

Title	Phase	Last Update
Comparing Retreatment of Lu-177-DOTATATE PRRT versus the Usual Treatment in Patients with Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial Phase 2 Last update: March 5	Phase 2	March 5
Testing the Addition of An Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiation-Based Treatment (Lutetium Lu-177 Dotatate) for Pancreatic Neuroendocrine Tumors Phase 1 Last update: March 5	Phase 1	March 5
Testing the Addition of Sunitinib Malate to Lutetium Lu-177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors Phase 1 Last update: March 5	Phase 1	March 5
A Phase 1 Study of Ga-68-R11228 and Lu-177-R11228 in Breast Cancer Phase 1 Last update: March 5	Phase 1	March 5
MANDARIN (S6371) Phase 3 Last update: March 5	Phase 3	March 5
Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu-177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells Phase 2 Last update: March 5	Phase 2	March 5
Real-world Use of Lutetium (Lu-177) Vipivotide Tetraxetan in China(PSMAreal CN) (PSMAreal) N/A Last update: March 5	N/A	March 5
Radiation Medication (Radium-223 Dichloride) versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy Phase 1 Last update: March 5	Phase 1	March 5
Testing Lutetium Lu-177 Dotatate in Patients with Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors Phase 2 Last update: March 5	Phase 2	March 5
Testing the Addition of Radium Therapy (Radium-223 Dichloride) to the Usual Chemotherapy Treatment (Paclitaxel) for Advanced Breast Cancer That Has Spread to the Bones Phase 2 Last update: March 5	Phase 2	March 5